Fibrosis–a common pathway to organ injury and failure
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
Fibrosis is a consequence of the inflammatory response. When fibrotic tissue becomes excessive, it can have diverse pathophysiological effects on a number of organ systems. The mechanisms underlying fibrosis and approaches to therapy are reviewed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hepatocyte injury, apoptosis and necrosis promote a sterile inflammatory response. This includes activation of KCs to clear necrotic debris, recruitment of lymphocytes and bone-marrow-derived monocytes, extracellular matrix (ECM) remodelling, myofibroblast activation, angiogenesis, and hepatocyte regeneration and differentiation to replace lost hepatocytes.11,31,32”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [31]
In the citing paper
“Both receptors are independently involved in regulation of cell adhesion, differentiation, proliferation of myofibroblasts and migration of both myofibroblasts and macrophages.31”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [31]
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Research works printed but not linked: 1
- TORAFIC Investigators Group, 2011, Clin Ther, 33, 1204.e3
Cited by
Items 401–500 of 1,001
Sun, C., Ma, Q., Yin, J., Zhang, H., & Liu, X. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00636-5 · Cited by 39
Xu, Q., Cheng, D., Liu, Y., Pan, H., Li, G., Li, P., Yan, L., Sun, W., Ma, D., & Ni, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16758 · Cited by 45
Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved
Delgado‐Valero, B., Cachofeiro, V., & Martínez‐Martínez, E. (2021) · Cells · doi:10.3390/cells10071824 · Cited by 42
Mehta, B. Y., Goodman, S. M., DiCarlo, E. F., Jannat‐Khah, D., Gibbons, J., Otero, M., Donlin, L. T., Pannellini, T., Robinson, W. H., Sculco, P. K., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03008-8 · Cited by 39
PFKFB3-Mediated Glycolysis Boosts Fibroblast Activation and Subsequent Kidney Fibrosis
Yang, Q., Huo, E., Cai, Y., Zhang, Z., Dong, C., Asara, J. M., & Wei, Q. (2023) · Cells · doi:10.3390/cells12162081 · Cited by 41
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases
Ezzo, M., & Hinz, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108528 · Cited by 41
Li, Y., Xu, H., Wang, Y., Zhu, Y., Xu, K., Yang, Z., Li, Y., & Guo, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02609-y · Cited by 39
Decoding fibrosis: Mechanisms and translational aspects
Schaefer, L. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.009 · Cited by 40
Higashi, A. Y., Aronow, B. J., & Dressler, G. R. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018060644 · Cited by 38
Exosomes: Carriers of Pro-Fibrotic Signals and Therapeutic Targets in Fibrosis
Li, M., Jiang, M., Meng, J., & Tao, L. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191209161443 · Cited by 38
PD-1/PD-L1 axis in organ fibrosis
Zhao, Y., Qu, Y., Hao, C., & Yao, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145682 · Cited by 48
She, L., Xu, D., Wang, Z., Zhang, Y., Wei, Q., Aa, J., Wang, G., Liu, B., & Xie, Y. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.05.002 · Cited by 37
Guo, L., Chen, L., Chen, F., Jiang, N., & Sui, L. (2019) · Europe PMC (PubMed Central) · Cited by 40
Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015–2020)
Li, X., Ding, Z., Wu, Z., Xu, Y., Yao, H., & Lin, K. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1896705 · Cited by 38
Willumsen, N., Jensen, C., Green, G. A., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04226-0 · Cited by 40
The versatility of macrophage heterogeneity in liver fibrosis
Gao, C.-C., Bai, J., Han, H., & Qin, H.-Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968879 · Cited by 37
p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling
Nagaraja, M. R., Tiwari, N., Shetty, S. K., Marudamuthu, A. S., Fan, L., Ostrom, R. S., Fu, J., Gopu, V., Radhakrishnan, V., Idell, S., et al. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.07.005 · Cited by 37
Gerckens, M., Schorpp, K., Pelizza, F., Wögrath, M., Reichau, K., Ma, H., Dworsky, A.-M., Sengupta, A., Stoleriu, M. G., Heinzelmann, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb3673 · Cited by 37
Rockey, D. C., Alsawas, M., Duarte‐Rojo, A., Patel, K., Levine, D., Asrani, S. K., Hasan, B., Nayfeh, T., Alsawaf, Y., Saadi, S. M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000841 · Cited by 46
Self-citationLevine, J. M. (2017) · Advances in Skin & Wound Care · doi:10.1097/01.asw.0000515077.61418.44 · Cited by 42
Specialized pro-resolving mediators in renal fibrosis
Brennan, E. P., Cacace, A., & Godson, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.05.001 · Cited by 36
Stribos, E. G. D., Seelen, M. A., van Goor, H., Olinga, P., & Mutsaers, H. A. M. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.01026 · Cited by 37
Wu, P., Liu, Z., Zhao, T., Xia, F., Gong, L., Zheng, Z., Chen, Z., Yang, T., & Duan, Q. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.158 · Cited by 38
c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis
Leslie, J., Macia, M. G., Luli, S., Worrell, J. C., Reilly, W. J., Paish, H. L., Knox, A., Barksby, B. S., Gee, L., Zaki, M. Y. W., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00306-2 · Cited by 39
Orphan nuclear receptor COUP-TFII enhances myofibroblast glycolysis leading to kidney fibrosis
Li, L., Galichon, P., Xiao, X., Figueroa‐Ramirez, A. C., Tamayo, D., Lee, J. J.-K., Kalocsay, M., Gonzalez-Sanchez, D. G., Chancay, M. S., McCracken, K. W., et al. (2021) · EMBO Reports · doi:10.15252/embr.202051169 · Cited by 38
Feng, Y., Chen, X., Wang, H., Chen, X., Lan, Z., Li, P., Cao, Y., Liu, M., Lv, J., Chen, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.664766 · Cited by 40
Role of Ferroptosis in Fibrotic Diseases
Zhou, J., Tan, Y., Wang, R., & Li, X. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s358470 · Cited by 40
Astaxanthin: A promising therapeutic agent for organ fibrosis
Li, K., Wang, W., & Xiao, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106657 · Cited by 40
Anti-fibrotic effect of wogonin in renal tubular epithelial cells via Smad3-dependent mechanisms
Meng, X., Ren, G., Gao, L., Li, H.-D., Wu, W., Li, X., Xu, T., Wang, X.-F., Ma, T., Li, Z., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.07.014 · Cited by 36
Molecular imaging of fibrosis using a novel collagen-binding peptide labelled with 99mTc on SPECT/CT
Zheng, L., Ding, X., Liu, K., Feng, S., Tang, B., Li, Q., Huang, D., & Yang, S. (2016) · Amino Acids · doi:10.1007/s00726-016-2328-7 · Cited by 36
CCAAT/Enhancer-Binding Proteins in Fibrosis: Complex Roles Beyond Conventional Understanding
Wang, L., Feng, J., Deng, Y., Yang, Q., Wei, Q., Ye, D., Rong, X., & Guo, J. (2022) · Research · doi:10.34133/2022/9891689 · Cited by 39
Hidvegi, T., Stolz, D. B., Alcorn, J. F., Yousem, S. A., Wang, J., Leme, A. S., Houghton, A. M., Hale, P. D., Ewing, M., Cai, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691253 · Cited by 38
Verzola, D., Milanesi, S., Viazzi, F. C., Ansaldo, F., Saio, M., Garibaldi, S., Carta, A., Costigliolo, F., Salvidio, G., Barisione, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62875-2 · Cited by 38
Four decades in the making: Collagen III and mechanisms of vascular Ehlers Danlos Syndrome
Omar, R., Malfait, F., & Agtmael, T. V. (2021) · Matrix Biology Plus · doi:10.1016/j.mbplus.2021.100090 · Cited by 43
Vukičević, S., Colliva, A., Kufner, V., Martinelli, V. C., Moimas, S., Vodret, S., Rumenović, V., Milošević, M., Brkljačić, B., Delić-Brkljačić, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27622-9 · Cited by 40
Vaccination-based immunotherapy to target profibrotic cells in liver and lung
Sobecki, M., Chen, J., Krzywińska, E., Nagarajan, S., Fan, Z., Nelius, E., Rodríguez, J. M. M., Seehusen, F., Hussein, A., Moschini, G., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.08.012 · Cited by 42
IL-6 trans-signaling is another pathway to upregulate Osteopontin
Uchibori, T., Matsuda, K., Shimodaira, T., Sugano, M., Uehara, T., & Honda, T. (2016) · Cytokine · doi:10.1016/j.cyto.2016.11.006 · Cited by 40
Pathomechanisms of renal Fabry disease
Eikrem, Ø., Skrunes, R., Tøndel, C., Leh, S. M., Houge, G., Svarstad, E., & Marti, H. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2609-9 · Cited by 35
Role of Circadian Transcription Factor Rev-Erb in Metabolism and Tissue Fibrosis
Raza, G. S., Sodum, N., Kaya, Y., & Herzig, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112954 · Cited by 38
Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease
Andoh, A., & Nishida, A. (2022) · Inflammatory Intestinal Diseases · doi:10.1159/000528312 · Cited by 40
Myeloid PFKFB3-mediated glycolysis promotes kidney fibrosis
Yang, Q., Huo, E., Cai, Y., Zhang, Z., Dong, C., Asara, J. M., Shi, H., & Wei, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259434 · Cited by 36
S100A8/A9 promotes endometrial fibrosis via regulating RAGE/JAK2/STAT3 signaling pathway
Xin, X., Liu, H., Zhang, S., Li, P., Zhao, X., Zhang, X., Li, S., Wu, S., Zhao, F., & Tan, J. (2024) · Communications Biology · doi:10.1038/s42003-024-05814-5 · Cited by 40
Akt mediated phosphorylation of LARP6; critical step in biosynthesis of type I collagen
Zhang, Y., & Stefanovic, B. (2016) · Scientific Reports · doi:10.1038/srep22597 · Cited by 34
Regulatory Mechanisms of the Molecular Pathways in Fibrosis Induced by MicroRNAs
Cui, Y., Zheng, S., Wu, H., & Shao-jun, C. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.190677 · Cited by 38
Lv, X.-M., Li, M.-D., Cheng, S., Liu, B., Liu, K., Zhang, C., Xu, X., & Zhang, M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.202 · Cited by 36
Liu, K., Cui, K., Feng, H., Li, R., Lin, H., Chen, Y., Zhang, Y., Chen, Z., Yuan, H., Li, M., et al. (2019) · Andrology · doi:10.1111/andr.12716 · Cited by 36
Linking LOXL2 to Cardiac Interstitial Fibrosis
Erasmus, M., Samodien, E., Lecour, S., Cour, M., Lorenzo, Ó., Dludla, P. V., Pheiffer, C., & Johnson, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165913 · Cited by 39
Zhou, R., Liao, J., Cai, D., Qin, T., Huang, E., Lü, T., Chen, S., & Xie, W. (2021) · The FASEB Journal · doi:10.1096/fj.202000926rr · Cited by 34
ER‐anchored CRTH2 antagonizes collagen biosynthesis and organ fibrosis via binding LARP6
Zuo, S., Wang, B., Liu, J., Kong, D., Cui, H. S., Jia, Y.-N., Wang, C., Xu, X., Chen, G., Wang, Y., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107403 · Cited by 35
Wu, P., Lin, B., Huang, S., Meng, J., Zhang, F., Zhou, M., Hei, X., Yu, K., Yang, H., & Huang, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846106 · Cited by 38
Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis
Cheng, H., Huang, H., Lee, T., Liao, Y., Sheng, Y.-H., Jin, P.-R., Huang, K., Chen, L.-H., Chen, Y., Lin, T., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.004 · Cited by 37
Pharmacological Inhibition of S100A4 Attenuates Fibroblast Activation and Renal Fibrosis
Wen, J., Jiao, B., Tran, M., & Wang, Y. (2022) · Cells · doi:10.3390/cells11172762 · Cited by 35
Myocardial fibrosis: Current aspects of the problem
Каретникова, В. Н., Кашталап, В. В., Косарева, С. Н., & Барбараш, О. Л. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh201789188-93 · Cited by 34
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications
Airola, C., Pallozzi, M., Cerrito, L., Santopaolo, F., Stella, L., Gasbarrini, A., & Ponziani, F. R. (2023) · Cells · doi:10.3390/cells12131712 · Cited by 37
Hu, X., Gan, L., Tang, Z., Lin, R., Liang, Z., Li, F., Zhu, C., Han, X., Zheng, R., Shen, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202307850 · Cited by 57
CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis
Mukhatayev, Z., Adilbayeva, A., & Kunz, J. (2024) · Cells · doi:10.3390/cells13110946 · Cited by 41
Madl, C. M., Wang, Y. X., Holbrook, C. A., Su, S., Shi, X., Byfield, F. J., Wicki, G., Flaig, I. A., & Blau, H. M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406787121 · Cited by 41
PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation
Zhu, X., Huo, Q., Jin, L., Du, J., Yu, J., Wang, H., Wu, N., Li, Y., Rui, Y., Zhao, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady1681 · Cited by 38
Biondo, L. A., Batatinha, H., de Souza, C. O., Teixeira, A. A. D. S., Silveira, L. S., Alonso‐Vale, M. I. C., Oyama, L. M., Alves, M. J., Seelaender, M. C. L., & Neto, J. C. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00452 · Cited by 39
siRNA-mediated protein knockdown in precision-cut lung slices
Ruigrok, M. J. R., Xian, J. L., Frijlink, H. W., Melgert, B. N., Hinrichs, W. L. J., & Olinga, P. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.11.005 · Cited by 35
Kaosombatwattana, U., Yamamura, T., Limsrivilai, J., Nakamura, M., Leelakusolvong, S., Hirooka, Y., & Goto, H. (2019) · Endoscopy International Open · doi:10.1055/a-0848-8225 · Cited by 33
Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule
Vijayaraj, P., Minasyan, A., Durra, A., Karumbayaram, S., Mehrabi, M., Aros, C. J., Ahadome, S. D., Shia, D. W., Chung, K., Sandlin, J. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.019 · Cited by 35
Ginsenosides: potential therapeutic source for fibrosis-associated human diseases
Li, X., Mo, N., & Li, Z. (2019) · Journal of Ginseng Research · doi:10.1016/j.jgr.2019.12.003 · Cited by 36
The Role of NLRP3 Inflammasome in Radiation-Induced Cardiovascular Injury
Huang, S., Che, J., Chu, Q., & Zhang, P. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00140 · Cited by 34
Shuai, W., Wen, J., Li, X., Wang, D., LI, Y., & Xiang, J. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.017 · Cited by 35
Proteomic landscape of TGF-β1-induced fibrogenesis in renal fibroblasts
Zhou, S., Yin, X., Mayr, M., Noor, M., Hylands, P. J., & Xu, Q. (2020) · Scientific Reports · doi:10.1038/s41598-020-75989-4 · Cited by 38
Prat‐Duran, J., Pinilla, E., Nørregaard, R., Simonsen, U., & Buus, N. H. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107787 · Cited by 34
Min, S., Zhu, M., Mao, X., Li, W., Wei, T., Mei, M., Zhang, Y., Wu, L., Yu, G., & Cong, X. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42052 · Cited by 34
The role of hepatic microenvironment in hepatic fibrosis development
Meng, Y., Zhao, T., Zhang, Z., & Zhang, D. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2132418 · Cited by 37
Genetic enhancement: an avenue to combat aging-related diseases
Cai, Y., Ji, Z., Wang, S., Zhang, W., Qu, J., Belmonte, J. C. I., & Liu, G.-H. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac054 · Cited by 33
p53 and Myofibroblast Apoptosis in Organ Fibrosis
McElhinney, K., Irnaten, M., & O'Brien, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076737 · Cited by 39
Yang, L., Lin, Z., Wang, Y., Li, C., Xu, W., Li, Q., Yao, W., Song, Z., & Liu, G. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0525-x · Cited by 33
Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie’s Disease
Mitsui, Y., Yamabe, F., Hori, S., Uetani, M., Kobayashi, H., Nagao, K., & Nakajima, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210133 · Cited by 40
Liu, H., Lai, W., Nie, H., Shi, Y., Zhu, L., Yang, L., Tian, L., Li, K., Bian, L., Xi, Z., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.108290 · Cited by 33
Rashidi, N., Harasymowicz, N. S., Savadipour, A., Steward, N. S., Tang, R., Oswald, S. J., & Guilak, F. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.12.034 · Cited by 40
Natural Products for Improving Soft Tissue Healing: Mechanisms, Innovations, and Clinical Potential
Alberts, A., Lungescu, I. A., Niculescu, A.-G., & Grumezescu, A. M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060758 · Cited by 38
Targeting TGFβ Signaling to Address Fibrosis Using Antisense Oligonucleotides
March, J. T., Golshirazi, G., Cernisova, V., Carr, H., Leong, Y., Lu‐Nguyen, N., & Popplewell, L. J. (2018) · Biomedicines · doi:10.3390/biomedicines6030074 · Cited by 37
Gerrits, T., Zandbergen, M., Wolterbeek, R., BRUIJN, J. A., Baelde, H. J., & Scharpfenecker, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207713 · Cited by 33
Cheng, C., Chu, C.-Y., Chen, H., Lin, I., Wu, C., Lee, Y.-K., Hu, P., & Bair, M. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.11.018 · Cited by 34
Preclinical rodent models of cardiac fibrosis
Wang, Y., Wang, M., Samuel, C. S., & Widdop, R. E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15450 · Cited by 35
CircRNAs: Decrypting the novel targets of fibrosis and aging
Yang, Y., Lei, W., Jiang, S., Ding, B., Wang, C., Chen, Y., Shi, W., Wu, Z., & Tian, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101390 · Cited by 37
Osteopontin - The stirring multifunctional regulatory factor in multisystem aging
Du, Y., Mao, L., Wang, Z., Yan, K., Zhang, L., & Zou, J. T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1014853 · Cited by 38
Fibro-Stenosing Crohn’s Disease: What Is New and What Is Next?
Solitano, V., Buono, A. D., Gabbiadini, R., Wozny, M., Repici, A., Spinelli, A., Vetrano, S., & Armuzzi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093052 · Cited by 37
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Chen, J., Yao, Y., Su, X., Shi, Y., Song, X., Xie, L., You, J., Tian, L., Yang, L., Fang, A., et al. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3587 · Cited by 34
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Dong, Q., Bao, H., Wang, J., Shi, W., Zou, X., Sheng, J., Gao, J., Guan, C., Xia, H., Li, J., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1120621 · Cited by 35
Wounds and the Microbiota: The Healing Interplay Between Host and Microbial Communities
Al-Taweel, R., Hammad, A. S., Tajammul, A., Crovella, S., & Al‐Asmakh, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311365 · Cited by 43
Malahias, M., Birch, G. A., Zhong, H., Sideris, A., Valle, A. G. D., Sculco, P. K., & Kirksey, M. (2020) · The Journal of Arthroplasty · doi:10.1016/j.arth.2020.02.046 · Cited by 31
Human Fibrosis: Is There Evidence for a Genetic Predisposition in Musculoskeletal Tissues?
Dagneaux, L., Owen, A. R., Bettencourt, J. W., Barlow, J. D., Amadio, P. C., Kocher, J. P. A., Morrey, M. E., Sánchez‐Sotelo, J., Berry, D. J., van Wijnen, A. J., et al. (2020) · The Journal of Arthroplasty · doi:10.1016/j.arth.2020.05.070 · Cited by 32
Metformin Attenuates Postinfarction Myocardial Fibrosis and Inflammation in Mice
Loi, H., Крамар, С., Laborde, C., Marsal, D. J., Pizzinat, N., Cussac, D., Roncalli, J. G., Boal, F., Tronchère, H., Oleshchuk, O., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179393 · Cited by 31
Epoxyeicosatrienoic Acids and Fibrosis: Recent Insights for the Novel Therapeutic Strategies
Guan, X., Rao, D., Liu, Y.-Z., Zhou, Y., & Yang, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910714 · Cited by 35
Position statement on the use of albumin in liver cirrhosis
Castro‐Narro, G., Moctezuma‐Velázquez, C., Malé-Velázquez, R., Trejo-Estrada, R., Bosques, F. J., Moreno-Alcantar, R., Rodríguez-Hernández, H., Bautista-Santos, A., Cortéz-Hernández, C. A., Reyes, E. C., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100708 · Cited by 33
Chen, Y., Zheng, Y., Iyer, S. R., Harders, G. E., Pan, S., Chen, H. H., Ichiki, T., Burnett, J. C. J., & Sangaralingham, S. J. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.024 · Cited by 31
Sirolimus-eluting airway stent reduces profibrotic Th17 cells and inhibits laryngotracheal stenosis
Motz, K., Lina, I. A., Samad, I., Murphy, M. K., Duvvuri, M., Davis, R. J., Gelbard, A. H., Chung, L., Chan‐Li, Y., Collins, S. L., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.158456 · Cited by 33
Brandon‐Warner, E., Benbow, J. H., Swet, J. H., Feilen, N. A., Culberson, C. R., McKillop, I. H., deLemos, A. S., Russo, M. W., & Schrum, L. W. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.035 · Cited by 33
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
Juillerat‐Jeanneret, L., Aubert, J., Mikulic, J., & Golshayan, D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00294 · Cited by 30
Menon, R. G., Raghavan, P., & Regatte, R. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-50715-x · Cited by 30
miR-1468-3p Promotes Aging-Related Cardiac Fibrosis
Lin, R., Rahtu‐Korpela, L., Magga, J. M., Ulvila, J., Swan, J., Kemppi, A., Pakanen, L., Porvari, K., Huikuri, H. V., Junttila, J. M., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.001 · Cited by 31
Long, F., Wang, Q., Yang, D., Zhu, M., Wang, J., Zhu, Y. Z., & Liu, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.115 · Cited by 32
Kondo, M., Suzuki, T., Kawano, Y., Kojima, S., Miyashiro, M., Matsumoto, A., Kania, G., Błyszczuk, P., Ross, R. L., Mulipa, P., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02899-3 · Cited by 34
Metadata
- Authors
- Rockey, D. C., Bell, P. D., & Hill, J. A.
- Affiliations
- Medical University of South Carolina (US)
- The University of Texas Southwestern Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-19
- Volume
- 372
- Issue
- 12
- Pages
- 1138-1149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1977437151
- Cited by
- 1,428
- References
- 118
- Citations by year
- 2026: 104 · 2025: 116 · 2024: 154 · 2023: 149 · 2022: 162 · 2021: 162 · 2020: 152 · 2019: 118 · 2018: 96 · 2017: 94 · 2016: 85 · 2015: 33
- FWCI
- 14.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- fibrosis, organ damage, organ failure, inflammation, fibrosis mechanisms, fibrosis treatment
- MeSH terms
- Fibrosis, Humans, Multiple Organ Failure, Transforming Growth Factor beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.